2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK
  5. CDK13 Isoform
  6. CDK13 Degrader

CDK13 Degrader

CDK13 Degraders (5):

Cat. No. Product Name Effect Purity
  • HY-151110A
    PROTAC CDK12/13 Degrader-1 TFA
    		Degrader 98.37%
    PROTAC CDK12/13 Degrader-1 (7f) TFA is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 TFA has anti-proliferative activity and can be used in breast cancer research.
  • HY-168555
    YJ1206
    		Degrader
    YJ1206 is an orally active, selective CDK12/CDK13 PROTAC degrader with an IC50 of 12.55 nM for in VCaP cells. YJ1206 increases DNA damage, induces apoptosis, and promotes tumor regression in orthotopic WA74 patient-derived xenograft (PDX) mice models of resistant prostate cancer. YJ1206 suppresses tumor growth in vivo in conjunction with AKT pathway inhibitors.
  • HY-168556
    YJ9069
    		Degrader
    YJ9069 is a selective CDK12/CDK13 PROTAC degrader with an IC50 of 22.22 nM for in VCaP cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. YJ9069 effectively inhibits proliferation in subsets of prostate cancer cells and significantly suppresses prostate tumor growth.
  • HY-151110
    PROTAC CDK12/13 Degrader-1
    		Degrader 98.01%
    PROTAC CDK12/13 Degrader-1 (7f) is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used in breast cancer research.
  • HY-168162
    ZLC491
    		Degrader
    ZLC491 is an orally active CDK12/13 PROTAC degrader. ZLC491 can be used in anticancer research.